Introduction: Diagnosis of myelodysplastic syndromes (MDSs) when anemia is the
Unfortunately, a diagnosis of MDS triggered by isolated anemia may be delayed until the degree of anemia becomes severe (transfusion dependency) and/or other cytopenias, or blasts, appear. 13 Research suggests that ~80% of MDS patients are diagnosed on the basis of symptoms related to anemia 14 ; however, earlier diagnosis and treatment, before the disease has become symptomatic, may be beneficial.
We undertook a prospective study to identify and characterize cases of unexplained anemia, with the ultimate aim of identifying patients with MDS, who may benefit from earlier rather than delayed treatment. Patients diagnosed with MDS underwent further investigation, including somatic mutation and survival analysis to determine outcomes following MDS diagnosis.
| ME THODS
This was a multicenter, prospective study conducted in the hema- 
| Patients and screening methods
We used a four-step screening process that began with the screen-
ing of routine hemograms and ended with the identification and characterization of MDS in a small proportion of patients ( Figure 1 ).
Step 1. Screening of patient hemograms, and identification of patients with Hb <12 g/dL and/or MCV >100 fL: We utilized an automated
informatics system to analyze the results from all hemograms performed in each laboratory during routine clinical practice. All patient cases with hemograms reporting a Hb level of <12 g/dL and/ or MCV > 100 fL were selected for further investigation.
Step 2. Exclusion of anemia due to known causes: We excluded all patients with conditions that may have caused the observed anemia.
This included a history of alcoholism and having had a hemogram ordered by the surgery, oncology, nephrology, or endocrinology departments. The remaining patients, who had anemia and/or macrocytosis of uncertain origin, were considered to have potential "hidden MDS."
Step 3. Formal enrollment into study and investigation of anemia of uncertain etiology: The patients with potential "hidden MDS"
were enrolled formally into the study and underwent further investigations to establish the etiology of the uncertain anemia.
The enrollment criteria for inclusion into this group were age ≥18 years, Hb <12 g/dL and/or MCV >100 fL, serum creatinine ≤2 mg/dL, hepatic function ≤2 times the upper limit of normal, not an alcoholic, and no prior diagnosis of a non-hematologic malignancy or any other condition that is known to cause anemia. Each patient underwent a complete PB evaluation, which was performed on the same day and using the same blood sample as the hemograms. The PB evaluation included analysis of reticulocyte count, PB smear, vitamin B12, folic acid, iron level, and ferritin levels, along with total iron-binding capacity, and renal, thyroid, and hepatic functions. In addition, the clinical histories of the selected cases, which were stored electronically in the hospitals' records systems, were reviewed in order to clarify the etiology of the anemia. A differential diagnosis was then reached using all available information and, if no cause of anemia or macrocytosis was found, patients were referred to the hematologist.
Step System (IPSS-R). 16 For patients with confirmed MDS, a mutational study of the most frequent myeloid genes involved was performed using next-generation sequencing (NGS) analysis (see below).
| NGS analysis of MDS patients
We carried out targeted gene sequencing using two NGS platforms, in accordance with each hospital's approach. In MDS patients from Valencia, a 39-gene panel (Table S1 ) was applied according to the instructions of the manufacturer of the Ion Torrent™ Proton System (Life Technologies, Carlsbad, CA, USA). Selected variants were annotated using Ion Reporter™, according to their mean coverage, presence in the healthy population (UCSC Common SNPs), the putative protein effect, and functional category.
In MDS patients from Salamanca, target-capture sequencing on the Illumina MiSeq platform (Illumina, San Diego, CA, USA) was performed across selected exons of 117 genes previously identified as being associated with MDS. This was conducted using a Nextera sequencing design that utilized Illumina DesignStudio (Illumina) ( Table S1 ). The Nextera Rapid Capture Custom Enrichment Kit (Illumina) used contains all the reagents necessary for the enrichment, indexing, and amplification of the samples. The manufacturer's instructions were followed for each procedure. The sequences were aligned to the reference genome (GRCh37/hg19) using MiSeq Reporter 2. Finally, variants with coverage <100 reads, <20 supporting reads, and variants with an allelic fraction lower than 3% were removed.
The remaining variants, evaluated as candidate somatic mutations, were finally flagged as oncogenic using criteria based on the information available, sequence conservation, and in silico prediction effect (SIFT, PolyPhen-2 and Mutation Taster).
| Statistics
Statistical analyses were conducted using IBM spss version 21.0 (IBM Corp., Armonk, NY, USA). Overall survival (OS) was defined as the time from diagnosis to death from any cause, and was estimated using the KM method.
| RE SULTS
A total of 137 453 hemograms were reviewed over the 3-month screening period. The hemograms were requested by a number of different doctors during routine clinical practice, according to local and regional policy. Due to internal resourcing constraints, Hospital GTiP in Badalona was only able to analyze patients during one prospective month of the screening period.
The initial electronic screening procedure conducted in step 1 selected 2702 patients (2% of the total) with anemia (Hb < 12 g/dL)
and/or macrocytosis (MCV > 100 fL) ( Table 1 ). In step 2, after carefully reviewing the biologic and clinical parameters of each patient using our electronic database, we excluded 2412 patients (89%) because a likely cause of anemia was found (eg, surgery, malignancy, alcoholism). This left 290 patients (11%), in whom the etiology of anemia and/or macrocytosis was still unknown. These patients were considered to have potential "hidden MDS."
In step 3, we used an algorithm to analyze the PB workup and clinical review, and subsequently establish a differential diagnosis in 139 patients (48% of the 290 patients with possible "hidden MDS").
In the 139 diagnosed patients, the most common causes of anemia were iron deficiency (n = 59; 42%), megaloblastic anemia (n = 39; 28%), and hematologic malignancies (n = 25; 18%) ( Table 1) . A diagnosis was not possible in the remaining 151 patients (52%), for a number of reasons (Table 1 ). These included older age (>90 years), the identification of comorbidities that can induce anemia, death, loss to follow-up, and resolution of anemia. A total of 25 patients were diagnosed with a hematologic disorder and subsequently referred for
TA B L E 1 Patient flow through the steps of the study and identification of the etiology of anemia

Hospital Salamanca
Hospital de la Ribera Germans Trias i Pujol Total
Length of study period (d) 69 63 37 169
Step Step 2
Number of patients with no immediate explanation for their anemia/macrocytosis a 180 102 8 290
Step 3 These patients proceeded to step 4 for further investigation (see Table 2 ).
bone marrow aspiration/biopsy in the cases, if indicated. MDS was the most common hematologic disorder (Table 2 ), being diagnosed in 14 patients (56% of patients who underwent bone marrow analysis). Three patients were diagnosed with acute myeloid leukemia (AML), three with monoclonal gammopathy of unknown significance (MGUS), two with thrombotic thrombocytopenic purpura (TTP), one with myeloproliferative neoplasm (MPNs), one with aplastic anemia (AA), and one with chronic lymphocytic leukemia (CLL). Table 3 provides a detailed description of each MDS patient identified in our study. The median age at diagnosis was 80 years (range, 58-91 years), and eight patients were male (57%). In all but two pa- According to the IPSS-R, 16 10 patients (77%) had a good prognosis (very good, good, and intermediate risk; IPSS-R score ≤3.5), while only three patients (23%) had poor prognosis (one and two patients had intermediate risk with IPSS-R score >3.5 and high-risk IPSS-R categorizations, respectively) ( Table 3) . Bone marrow was not available from one patient (patient 7), although MDS-EB-2 was suspected based on the PB smear, and the patient experienced AML progression 3 months later. Six patients were transfusion-dependent at diagnosis and had developed transfusion dependence just prior to diagnosis.
| Characteristics, treatment, and outcomes of patients with MDS
Among the 10 lower-risk MDS patients, six required treatment after diagnosis. Five received erythroid and/or granulocyte stimulating agents (ESAs +/− G-CSF), and one received only red blood cell transfusions (Table 3) . Median time from diagnosis to ESA treatment was 45 days (range, 21-52 days). Iron chelation therapy was initiated in two patients, and lenalidomide was administered to one patient with a del(5q) cytogenetic abnormality after loss of response to ESAs.
Of the three patients with higher-risk MDS, two received best supportive care only, while hypomethylating drug treatment (four cycles) was started in the third patient 25 days after diagnosis ( (Figure 2A ). OS was significantly better at 30 months in patients with lower-risk compared with higher-risk MDS (100% vs 0%; log-rank P < 0.001) ( Figure 2B ).
| Somatic myeloid mutations in the MDS cohort
Next-generation sequencing analysis was performed in 13 out of 14 newly diagnosed MDS patients. Mutations were identified in 12 patients (92% of those analyzed). Among the 10 lower-risk MDS patients, the K700E mutation in SF3B1 was the most frequent, being identified in six patients, all of whom had ring sideroblasts in their bone marrow (Table 3) . Two patients with the SF3B1 mutation had No mutations were found in the remaining lower-risk patient (MDS with multilineage dysplasia).
Of the three higher-risk patients, one had a ZRSR2 mutation and two had TP53 mutations ( Table 3 ). The presence of these two mutations was correlated with poor prognosis (Figure 2C ), compared with the presence of SF3B1/other mutations (median OS: 10 months vs not reached for patients with TP53/ZRSR2 mutations and SF3B1/ other mutations, respectively; P < 0.001).
| D ISCUSS I ON
The identification of anemia is a concern in individuals of all ages, but especially in the elderly, as it may aggravate comorbidities, increase mortality risk, and limit quality of life. The etiology of anemia is heterogeneous, however, and obtaining a final diagnosis may be difficult
Hematologic disorders Total (n = 25)
Myelodysplastic syndrome 14 (56%)
Acute myeloid leukemia 3
Monoclonal gammopathy of unknown significance 3
Thrombotic thrombocytopenic purpura 2
Chronic myeloproliferative neoplasm 1
Aplastic anemia 1
Chronic lymphocytic leukemia 1 TA B L E 2 Hematologic disorders identified in step 4 of the study 
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and time-consuming, potentially requiring the involvement of many specialists. 17 Patients presenting with anemia, and particularly elderly patients, often require repeated tests and may see several different specialists before the cause of their anemia is determined, or before they are referred to a hematologist. The sometimes-arduous path to obtaining a diagnosis may lead to greater healthcare spending, and negatively impact patients' quality of life. 18, 19 To our knowledge, ours is the first prospective study utilizing should be confirmed by other prospective and retrospective studies. In our study, the patients diagnosed with MDS corresponded to 10% of screened cases and 56% of hematologic disorders diagnosed ( Figure 1 ). Our results support that patients with anemic MDS may not be referred to a hematologist as soon as the cytopenia appears, but only when the anemia is severe or symptomatic. 21 All but one of the patients in our study presented with anemia as an isolated cytopenia, and all of them showed macrocytosis at the time of diagnosis.
In this regard, diagnosis may be more complicated due to the absence of other cytopenias that otherwise might help identify MDS.
17
In five patients, our laboratory-based approach facilitated the diagnosis of anemia before it became symptomatic, allowing treatment before it became severe (ie, requiring red blood cell transfusions), potentially improving quality of life and reducing the number of diagnosisrelated hospital visits. Median time from diagnosis to treatment in our study was 45 days (range, 21-52 days) for lower-risk patients, while in other studies of lower-risk newly diagnosed MDS patients, it was 130 days (range, 60-450 days; ARCADE study) and 92 days (range, 1-5683 days; SPRESAS study [Spanish registry of ESAs in anemic lowrisk MDS patients]) 22, 23 The estimated 3-year OS in the MDS patients we diagnosed was 71% and was significantly higher among lower-risk (IPSS-R ≤ 3.5) than higher-risk patients (IPSS-R > 3.5; 100% vs 0%; P < .001), consistent with previous reports. 16, 24, 25 Recently, somatic mutations have been described in >80%-90%
of patients with MDS. 26 The presence of myeloid mutations appears to be related to MDS pathogenesis; for example, the SF3B1 mutation induces the formation of ring sideroblasts and other MDS-specific phenotypes. Mutations involving the spliceosome machinery, such as those of the ZRSR2 and SF3B1 genes, have been identified in MDS, and genotype is believed to be clearly correlated with a specific phenotype and prognosis. 27 Accurate identification of these mutations may assist in diagnosis, by confirming clonal hematopoiesis, and in prognostication, by enhancing risk stratification using the IPSS-R.
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F I G U R E 2 Overall survival in (A) all patients with MDS (n = 14); (B) patients with lower-risk disease (IPSS-R score ≤3.5; n = 10) and higherrisk disease (IPSS-R score >3.5; n = 3); (C) patients with somatic mutations (n = 12; log-rank test P < 0.001). MDS, myelodysplastic syndrome; IPSS-R, Revised International Prognostic Scoring System; OS, overall survival
In this regard, the recent characterization of mutations in MDS patients indicates that the integration of somatic mutations into the MDS diagnostic flowchart could improve our ability to capture diagnostic and prognostic information in patients with MDS, improving clinical decision making. 29 Furthermore, because this group of patients may benefit from early treatment, identification of somatic mutations could identify clonal hematopoiesis and guide an early therapeutic approach. 30 The current update of the WHO classification for myeloid malignancies includes the presence of SF3B1 mutation in the diagnostic criteria for MDS with ring sideroblasts. 15 In our study, the hot spot mutation in SF3B1 was the most frequent finding on NGS analysis, correlating with the presence of ring sideroblasts in bone marrow (100%) and lower-risk MDS, in agreement with previous data. 27, [31] [32] [33] It should be noted that the majority of our patients were lower-risk MDS cases carrying SF3B1 mutations. Recently, it has been shown that patients with ring sideroblasts, and specifically those with SF3B1 mutation, respond best to the TGF-β1 inhibitor, luspatercept. It would be interesting to examine whether patients who are diagnosed early would benefit from early treatment, preventing the need for red blood cell transfusions. 34 Other studies have shown that investigating somatic mutations using NGS improves diagnosis among patients with cytopenia of uncertain etiology (ICUS). 29, 31, 35 Bejar and colleagues performed a prospective study to examine the frequency and types of mutations encountered in 144 patients with unexplained cytopenia. In total, 35% of ICUS patients carried a somatic mutation or chromosomal abnormality indicative of clonal hematopoiesis, suggesting that additional research into the clinical significance of somatic mutations in ICUS patients is needed. 31 Further investigation of patients diagnosed with ICUS is currently under review. 35 In our study of patients with anemia of uncertain etiology, no ICUS was detected. This is possibly related to the exclusion of 151 patients due to older age and/or comorbidities that precluded further investigation. It seems reasonable to expect that older patients in our study may have had a higher incidence of clonal hematopoiesis, as the incidence of clonal hematopoiesis increases with age. 36 In this context, recent advances in NGS have detected myeloid neoplasm-related mutations in patients who do not meet the diagnostic criteria for MDS and various terms have been adopted to describe these cases, including clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of undetermined significance (CCUS). These diagnoses are challenging and also require additional hit(s) to complete a neoplastic hematopoiesis. 37 We found that TP53 and ZRSR2 mutations were associated with poor survival. All patients with these mutations died 20 months after diagnosis, although patient numbers were very small. In comparison, outcomes were better in patients carrying other mutations (SF3B1 or TET2; P = 0.001). In another study, inclusion of molecular alterations such as EZH2 and TP53 mutations in the group of clinical parameters considered during prognostic stratification of MDS allowed the lowerrisk MDS score to be redefined, demonstrating that a pan-myeloid gene panel has diagnostic and prognostic utility in these diseases. 31 Improvement in outcomes for MDS patients will depend on how quickly we can identify and treat them. Fortunately, it seems likely that, in the near future, the exploitation of molecular characteristics as a basis for new treatment approaches will change the natural course of the disease, leading to better management of MDS patients.
Our study allowed the identification of 114 patients whose anemia
was not due to hematologic disorders. These included anemia related to deficiencies of iron or thyroid hormones. In addition, 25 hematologic disorders, including 11 that were not MDS, were diagnosed using this approach, enabling early treatment for these patients. This prompt treatment was very important for some patients, such as those with AML, TTP, AA, and autoimmune hemolytic anemia. It is particularly noteworthy that with a single PB analysis, patients with suspected hematologic disorders and/or malignancies could be identified and rapidly investigated further. We suggest that a correct diagnosis for anemia of unknown origin could be easily obtained if this approach, utilizing blood cell counts and revision of PB smears, is adopted. This approach, combined with a review of clinical data and laboratory tests, was sufficient to clarify other causes of anemia. Of note, the multistep and multiinvestigational nature of our procedure requires collaboration between laboratory personnel, clinical physicians, and hematology specialists.
| CON CLUS IONS
We believe that the prospective, four-step approach we have taken is an efficient and logical strategy to facilitate the diagnosis of MDS on the basis of unexplained anemia and/or macrocytosis. This procedure may allow the early diagnosis of the most serious causes of anemia, including MDS, enabling early treatment and, ultimately, improved outcomes. In addition to identifying patients with MDS, our unique approach may facilitate identification and treatment of patients with anemia of other etiologies such as iron, megaloblastic, and thyroid hormone deficiency. Our results indicate that complementary molecular analysis of genes related to MDS is a promising diagnostic and prognostic approach that could be readily applied to routine clinical practice. Our findings require confirmation in a larger series, which would facilitate more accurate analysis of longterm morbidity and mortality in both MDS and non-MDS patients.
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